**To:** [redacted] 5.1.2i @rivm.nl]
**From:** [redacted] 5.1.2e
**Sent:** Thur 9/17/2020 11:48:43 PM
**Subject:** FW: Meeting on assay details Eurofins Genomics SARS-CoV2-qPCR
**Received:** Thur 9/17/2020 11:48:43 PM
Eurofins [redacted] 5.1.2a confirmations.xlsx

Voor archivering

Mvg

[redacted] 5.1.2e

---

**From:** [redacted] 5.1.2e
**Sent:** donderdag 17 september 2020 16:47
**To:** [redacted] 5.1.2e < [redacted] 5.1.2e @nmdl-lcpl.nl>; [redacted] 5.1.2e @eurofins.com' < [redacted] 5.1.2e @eurofins.com>; [redacted] 5.1.2e < [redacted] 5.1.2e @eurofins.com>; [redacted] 5.1.2e < [redacted] 5.1.2e @eurofins.com>; [redacted] 5.1.2e < [redacted] 5.1.2e @lcdk.nl>; [redacted] 5.1.2e < [redacted] 5.1.2e @lcdk.nl>; [redacted] 5.1.2e < [redacted] 5.1.2e @eurofins.com>; [redacted] 5.1.2e < [redacted] 5.1.2e @scal.nl>; [redacted] 5.1.2e < [redacted] 5.1.2e @leversteijn.nl>
**Subject:** RE: Meeting on assay details Eurofins Genomics SARS-CoV2-qPCR

Dear all,

Please find attached an update of the data with results of this afternoon. This is the final version.

Best regards,

[redacted] 5.1.2e

---

**From:** [redacted] 5.1.2e
**Sent:** donderdag 17 september 2020 14:46
**To:** [redacted] 5.1.2e < [redacted] 5.1.2e @nmdl-lcpl.nl>; [redacted] 5.1.2e @eurofins.com; [redacted] 5.1.2e < [redacted] 5.1.2e @eurofins.com>; [redacted] 5.1.2e < [redacted] 5.1.2e @eurofins.com>; [redacted] 5.1.2e < [redacted] 5.1.2e @lcdk.nl>; [redacted] 5.1.2e < [redacted] 5.1.2e @lcdk.nl>; [redacted] 5.1.2e < [redacted] 5.1.2e @eurofins.com>; [redacted] 5.1.2e < [redacted] 5.1.2e @scal.nl>; [redacted] 5.1.2e < [redacted] 5.1.2e @leversteijn.nl>
**Subject:** RE: Meeting on assay details Eurofins Genomics SARS-CoV2-qPCR

Dear all,

Please find attached the confirmations that have been performed.

There are some not concordant results from both sides. Always in the higher Ct range, and obviously related to measuring around the LOD of the used RT-PCR assay workflows, extractions included. If these samples were repeated many time I expect that they become positive in only a fraction of the repeats.

I added the curves kindly shared by [redacted] 5.1.2e and our curves for the discrepant results.

For discussion this afternoon.

Best regards,

[redacted] 5.1.2e

-----Original Appointment-----
**From:** [redacted] 5.1.2e < [redacted] 5.1.2e @nmdl-lcpl.nl>
**Sent:** donderdag 17 september 2020 11:54
**To:** [redacted] 5.1.2e ; [redacted] 5.1.2e @eurofins.com; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e ; [redacted] 5.1.2e
**Subject:** Meeting on assay details Eurofins Genomics SARS-CoV2-qPCR
**When:** donderdag 17 september 2020 17:00-18:00 (UTC+01:00) Amsterdam, Berlijn, Bern, Rome, Stockholm, Wenen.
**Where:** Microsoft Teams Meeting

Join Microsoft Teams Meeting

Learn more about Teams | Meeting options